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The Candida (C.) albicans complex includes C. albicans, C. dubliniensis, C. stellatoidea, and C. africana, with the last
mentioned as an important emerging agent of vulvovaginal candidiasis (VVC). The aim of the study was to
identify C. africana and C. dubliniensis and assess their drug susceptibility in vaginitis. One-hundred Candida
isolates of the C. albicans complex from women diagnosed with vaginitis and from vaginal samples in the culture
collection of a medical mycology laboratory were examined. Species of the C. albicans complex were identified
with conventional and molecular methods using polymerase chain reaction (PCR) for amplification and
sequencing of the internal transcribed spacer (ITS) region, PCR for partial amplification of hyphal wall protein 1
(HWP1) gene and duplex PCR. The effects of antifungal drugs were evaluated according to standard broth
microdilution protocols.
Ninety-seven C. albicans (97%) and three C. africana (3%) isolates were identified. Results of susceptibility
testing revealed one isolate of C. africana to be resistant to both clotrimazole and fluconazole, and one showed
reduced susceptibility to itraconazole.
Identification of Candida species especially C. africana in vaginitis is crucial, there are varying levels of resis-
tance to antifungal drugs.1. Introduction
Species in the C. albicans complex can colonize in the vaginal tract.
Through changes in the relationship between the host and this
commensal yeast, an invasive form may occur (Goncalves et al., 2016)
causing mucosal infection and vulvovaginal candidiasis (VVC) (Hedayati
et al., 2015). In 2001, C. albicans isolates of African and German patients
with atypical phenotypes were described as a novel species, C. africana
(Tietz et al., 2001). C. africana produces a germ tube but not chla-
mydospores. C. albicans remains the most common pathogenic yeast
isolated from vaginal specimens of VVC patients, but the closely-related
C. africana and C. dubliniensis have often been mistaken for C. albicans.
C. africana has been isolated from candidal balanoposthitis in China (Huar3@gmail.com (S. Farahyar).
September 2019; Accepted 13 M
is an open access article under tet al., 2015), and clinical isolates have been reported as the cause of VVC
in Germany, China, Italy, Iran, Nigeria, Spain, the United Kingdom,
Argentina, Colombia, among other countries (Tietz et al., 2001; Alon-
so-Vargas et al., 2008; Romeo and Criseo, 2009; Dieng et al., 2012; Nnadi
et al., 2012; Borman et al., 2013; Shan et al., 2014; Rodriguez-Leguiza-
mon et al., 2015; Yazdanparast et al., 2015; Theill et al., 2016). The
vaginal candidiasis studies in Iran have been identified susceptible
(Yazdanparast et al., 2015) and resistant (Majdabadi et al., 2018) anti-
fungal drugs C. africana isolates.
Molecular methods are suitable for identification of Candida species.
The use of the ribosomal DNA (rDNA) ITS region for sequence-analysis
appears to be the most sensitive and specific method for accurate and
reliable molecular identification of Candida species (Merseguel et al.,arch 2020
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ITS2 region has been shown effective in detecting the presence of
C. africana in clinical Candida infections (Borman et al., 2013). Duplex
PCR is a suitable method for identification of isolates such as C. albicans
and C. dubliniensis (Ahmad et al., 2012). Amplification of the HWP1 gene
was the first molecular method for discriminating C. albicans,
C. dubliniensis, and C. africana (Romeo and Criseo, 2008). Many anti-
fungal agents are effective treating VVC, but some vaginal Candida iso-
lates have developed resistance to antifungal drugs. Assessment of
antifungal susceptibility of pathogenic yeasts is essential to proper
therapy and will allow evaluation of their efficacy and treatment results
as well as prevention of drug resistance (Mukasa et al., 2015; Fornari
et al., 2016). However, there is limited information about the prevalence
and antifungal susceptibility of C. africana in VVC in Iran. The aim of this
study was to identify C. africana and C. dubliniensis in vaginal samples
from VVC patients and to evaluate their antifungal susceptibility pattern.
2. Materials and methods
2.1. Patients, sample collection and definitions
The present study analyzed clinical isolates of vaginal discharge from
300 non-pregnant patients aged 18–57 years with suspected VVC
admitted to the Shahid Akbar Abadi hospital and Shahriar health centers
from June through December 2016, along with culture samples from our
laboratory. Patients had not used antifungal drugs within the preceding
four weeks. Samples were collected with sterile cotton swabs, and
microscopic examination was done to identify yeast forms or pseudo-
hyphae. In addition, 30 Candida spp. of the C. albicans complex obtained
from VVC patients were selected from the culture collection of the
medical mycology laboratory in our department. All specimens were
cultured on CHROMagar Candida medium (CHROMagar, France) at 37
C for 24–48 hrs for detection of mixed Candida spp. infections. A single
colony of each Candida isolate on CHROMagar Candida medium was
selected and cultured on Sabouraud dextrose agar (SDA) medium with
chloramphenicol at 30 C for 48–72 hrs for further use. The germ tube
test, chlamydospore-forming assay on corn meal agar (CMA) with 1%
Tween 80 and growth on SDA medium with chloramphenicol at 42 C
and 45 C was conducted.
2.2. DNA extraction
A single colony of each clinical isolate from CHROMagar Candida
medium was cultured on yeast extract peptone dextrose (YEPD) agar and
incubated at 37 C for 24–48 hrs. Genomic DNAwas extracted from yeast
cultures using the Qiagen DNA tissue kit (Germany). The extracted DNA
was stored at -20 C until use.
2.3. PCR amplification and sequencing of ITS region
The universal primers ITS1 (50-TCCGTAGGTGAACCTGCGG-30) and
ITS4 (50-TCCTCC GCTTATTGATATGC-30) were used to amplify the ITS1-
5.8S-ITS2 region (Fujita et al., 2001; Ciardo et al., 2006) under the
following conditions: 98 C at 5 min; 35 cycles of 30 s at 98 C, annealing
for 30 s at 56 C, 30 s at 72 C, and a final extension of 5 min at 72 C. The
PCR products were sequenced by Macrogen (Korea). Sequences were
compared with reference data available from the GenBank database
using the BLAST sequence search tool (http://www.ncbi.nlm.nih.
gov/BLAST).
2.4. Duplex PCR
C. albicans and C. dubliniensis strains were analyzed by duplex PCR
with paired primers CALF (50-TGGTAAGGCGGGATCGCTT-30) and CALR
(50-GGTCAAAGTTTGAAGATATAC-30) for C. albicans and CDUF (50-
AAACTTGTCACGAGATTATTTTT-30) and CDUR (50-AAAGTTTGAAG2
AATAAAATGGC-30) for C. dubliniensis (Ahmad et al., 2012). Specific
primers used the following PCR protocol: 95 C for 5 min; 30 cycles of 1
min at 95 C, 30 s at annealing temperature 55 C, and 1 min at 72 C;
and a final extension of 10 min at 72 C.
2.5. PCR amplification of HWP1 gene
The PCR primers (CR-f 50-GCTACCACTTCAGAATCATCATC-30 and
CR-r 50-GCACCTTCAGTCGTAGAGACG-30) used to amplify the HWP1
gene for detection C. albicans, C. africana and C. dubliniensis, as previously
described by Romeo and Criseo (2008).
Reference strains used as control were C. albicans (ATCC10231) and
C. dubliniensis from the archives of department of Medical Parasitology
and Mycology, School of Medicine, Iran University of Medical Sciences.
C. dubliniensis was 100% confirmed by sequencing to species level.
2.6. In vitro antifungal susceptibility testing
The in vitro susceptibility was determined by the Clinical and Labo-
ratory Standards Institute (CLSI) (CLSI M27-S3 2008; CLSI M27-S4
2012). Briefly, final inocula of 0.5103 to 2.5103 colony-forming
units/ml were distributed in 96 well microtiter plates in RPMI 1640
medium buffered to pH 7.0 with 0.165M morpholinepropanesulfonic
acid with diluted antifungal drugs and incubated at 35 C. The antifun-
gals used were amphotericin B, itraconazole, fluconazole, and clotrima-
zole (Sigma, Germany), and all tests were duplicated. C. glabrata CBS 138
was used as quality control strain. According to CLSI M27-S3 criteria for
fluconazole, the sensitivity profile is classified as sensitive (8 μg/ml),
dose-dependent sensitive (16–32 μg/ml), and resistant (64 μg/ml), and
breakpoints for itraconazole is sensitive (0.125 μg/ml), dose-dependent
sensitive (0.25–0.5 μg/ml), and resistant (1 μg/ml).
2.7. Ethical approval
This research was approved by Ethics Committee of Iran University of
Medical Sciences, under Ethics Committee number 95-01-30-27842.
2.8. Informed consent
Written informed consent was obtained from all patients.
3. Results
3.1. Patients
All patients diagnosed with VVC (23%) were in the 18–50 years age
range. None exhibited diabetes, immunodeficiency, or other chronic
disease. The archival information on VVC patients indicated a very
similar age range, 18–50 years, and without disease.
3.2. Yeast isolates
One hundred isolates belonging to the C. albicans complex were
identified, 97 as C. albicans (data not shown) 97% and three (3%) as C.
africana. C. africana produced small turquoise-green colonies on CHRO-
Magar Candida and did not produce chlamydospores on CMA medium.
C. albicans isolates proliferated at 42 C and 45 C, while the C. africana
isolates did not.
3.3. Duplex PCR assay
The results of amplification of isolates with CALF/CALR and CDUF/
CDUR specific primers for C. albicans and C. dubliniensis, respectively, for
duplex PCR assay, were determined for a ~100 bp fragment of C. albicans
and a ~325 bp fragment of C. dubliniensis (Figure 1). No C. dubliniensis
isolates were found in this study.
Figure 1. Agarose gel of duplex PCR using primers CALF, CALR, CDUF andC-
DUR. Lane 1: C. albicans clinical isolate (~100 bp); Lane 2: positive control
C. dubliniensis (~325 bp) from the archives of the Department of Medical
Parasitology and Mycology; Lane 3: positive controls C. albicans (ATCC10231)
and C. dubliniensis. N: negative control. M: marker 100 bp.
Figure 3. Agarose gel of PCR amplification with specific primers of HWP1 gene;
Lane 1: C. albicans (ATCC10231) ~900 bp; Lanes 2–4: C. africana (~700 bp);
Lane 5: positive control of C. dubliniensis (~560 bp) from the archives of the
Department of Medical Parasitology and Mycology; N: negative control. M:
marker 100 bp.
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Amplification of all clinical isolates of C. albicans complex with ITS1
and ITS4 primers yielded fragments of 530 bp for both C. albicans and
C. africana (Figure 2). The ITS region sequences of Candida spp. clinical
isolates were compared in the GenBank database using BLAST. All clin-
ical isolates showed 100% and 99% similarity to C. albicans or C. africana.
The ITS sequences of C. africana isolates were deposited in GenBank
under accession numbers MG757669, MG757670, and MG757671.
3.5. PCR amplification with specific primers of HWP1 gene
The results of partial amplification of isolates with specific primers of
HWP1 gene yielded fragments of ~900 bp, ~700 bp and ~560 bp for
C. albicans, C. africana and C. dubliniensis, respectively (Figure 3).Figure 2. Clinical isolates of C. albicans complex analyzed with ITS1 and ITS4
universal primers; 530 bp fragment produced. Lanes 1–8: C. albicans; Lanes
9–11: C. africana; N: negative control. M: marker 50 bp.
3
3.6. Antifungal susceptibility testing
Candida africana isolates were classified as sensitive, dose-dependent
sensitive, or resistant to antifungal agents based on their minimum
inhibitory concentration (MIC) according to the M27-S3 protocol
(Table 1). One isolate of C. africana isolates showed resistance to both
clotrimazole (MIC  1 μg/ml) (Pelletier et al., 2000) and fluconazole
(MIC  64 μg/ml). One isolate showed susceptibity in a dose-dependent
manner to itraconazole (0.25–0.5 μg/ml). Clinical C. africana isolates
were susceptible to amphotericin B.
4. Discussion
The female genital tract is a common site of pathogenic growth of
Candida spp., and VVC is a common infection. C. albicans is reported to
be the most common yeast species involved in VVC (Alizadeh et al.,
2017; Kord et al., 2017; Khorsand et al., 2015). Species of C. albicans
complex include C. albicans, C. dubliniensis, C. africana and C. stellatoidea
that are important in vaginitis, with C. albicans the primary agent of
Candida infections. C. dubliniensis was identified as the most common
cause of oral candidiasis in HIV-infected individuals (Sullivan et al.,
2005). Accurate identification of these closely related yeasts is facili-
tated by the use of both conventional and molecular methods.
C. africana (6%) has been reported to be more prevalent than
C. dubliniensis (Borman et al., 2013), with worldwide distribution
identified from vaginal discharge, candidal balanoposthitis, and blood
culture (Odds et al., 2007; Romeo and Criseo, 2011; Romeo et al., 2013;
Hu et al., 2015). The present study confirmed C. africana (3%), in the C.
albicans complex, as an important agent of VVC. In order to administer
effective treatment, the species must be identified, since some show
resistance to antifungal drugs. The HWP1 gene amplification is adequate
to identify species of this complex (Hu et al., 2015), and sequencing of
the ITS region has proven to be a feasible method for the reliable
identification of clinically important yeasts. C. dubliniensis and
C. stellatoidea were not detected in our study. Other studies of VVC have
also not reported C. dubliniensis isolate (Nnadi et al., 2012; Shan et al.,
2014; Hu et al., 2015; Ngouana et al., 2015) while some have found it to
have higher prevalence than C. africana (Borman et al., 2013; Theill
et al., 2016). Romeo et al. (Romeo and Criseo, 2009) studied isolates of
C. albicans (338), C. africana (27), and C. dubliniensis (11) from several
anatomical sites and found C. albicans (89.9%) to be the most common
species, followed by C. africana (7.2%) and C. dubliniensis (2.9%), with
C. africana isolated only from vaginal secretions. An investigation from
China (Hu et al., 2015) found five C. africana isolates (6.3%) involved in
candidal balanoposthitis to be susceptible to fluconazole, itraconazole,
Table 1. In vitro susceptibility profile of three C. africana vaginal isolates using the breakpoints of CLSI M27- S3a.




C. africana Fluconazole 0.25–64 2 - 1
Clotrimazole 0.06–16 2 - 1
Itraconazole 0.06–16 2 1 -
Amphotericin B 0.06–2.0 3 - -
a CLSI document M27- S3 (2008).
b S: sensitive.
c S-DD: susceptible dose-dependent.
d R: resistant.
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amphotericin B. Shan et al. (2014) reported that C. africana isolates
(1.5%) from vaginal specimens from China were susceptible to nystatin,
fluconazole, itraconazole, miconazole, and clotrimazole, while another
study reported five (4.38 %) C. africana VVC isolates to be susceptible to
tested antifungal agents (Yazdanparast et al., 2015). Theill et al. (2016)
showed low MIC values of nystatin, fluconazole, itraconazole, vor-
iconazole, clotrimazole, and terbinafine to C. africana and C. dubliniensis
vaginal isolates. Borman et al. (2013) showed C. africana isolates to be
susceptible to tested antifungal agents suitable for VVC treatment.
Ngouana et al. (2015) reported a C. africana isolate in vaginal samples
from HIV infected patients to be resistant to ketoconazole and exhibit
reduced susceptibility to amphotericin B. Majdabadi et al., isolated two
C. africana of vaginal candidiasis in which one species was resistant to
fluconazole and itraconazole, the other one to itraconazole (Majdabadi
et al., 2018). We found one C. africana vaginal isolate resistant to both
clotrimazole and fluconazole, and another one showed dose-dependent
susceptibility to itraconazole.
5. Conclusion
Our finding of C. africana as a rare agent of vaginitis resistant to both
clotrimazole and fluconazole with reduced susceptibility to itraconazole
is important in VVC treatment. Identification of C. africana as an un-
common agent of VVC is critical, since this yeast showed a range of
susceptibility to antifungal agents.
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